xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns="http://www.w3.org/TR/REC-html40">
http://bmj.com/cgi/content/full/322/7295/1143/a


|
|
|
Collections
under which this article appears:
Drug misuse
|
BMJ 2001;322:1143 ( 12 May )
News roundup
Time release analgesic causes fatal overdoses in United States
Fred Charatan Florida
Oxycodone hydrochloride (OxyContin) is believed to be responsible for more
than 120 fatal overdoses among drug misusers in recent years in several states,
including Maine, Kentucky, Virginia, and Florida.
The drug, manufactured by Purdue Pharma of Stamford, Connecticut, contains a
synthetic form of morphine in a sustained release tablet and is prescribed for
chronic pain. It was approved by the Food and Drug Administration in 1995 and
is the leading narcotic analgesic sold in tablet form in the United States.
Last year, sales exceeded $1bn (£714m).
Its time release formulation enables the active ingredient to work over many
hours. Drug misusers discovered, however, that they could defeat the time
release design by crushing or dissolving the tablet, enabling them to snort or
inject the narcotic. The government has said that no prescription drug in the past
20 years has been so widely misused so soon after its release as this one.
In recent years, up until last December, Purdue Pharma marketed the drug
aggressively by paying the hotel and travel expenses of hundreds of doctors who
attended weekend "pain management" seminars in holiday places such as
Florida. The company has also held about 7000 seminars around the country for
doctors, including many general practitioners, which advocated the use of
powerful, long acting narcotics such as oxycodone hydrochloride in pain
treatment.
Alarmed by the growing number of reports of deaths from the drug, the Drug
Enforcement Administration (DEA) made an unprecedented move by asking Purdue
Pharma to limit the drugs distribution to only those specialists who regularly
treat patients for chronic or severe pain.
Purdue Pharma officials said, "We expect to have ongoing, constructive
dialogue with the DEA on this subject. We do not think it would be appropriate
to go into any specifics at this time."
|
|
|
Collections
under which this article appears:
Drug misuse
|


ALL
INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR
GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE
KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED
AS PROVIDING MEDICAL OR LEGAL ADVICE. THE DECISION WHETHER OR NOT TO
VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU
ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.